STAT+: Argenx sees unusual setback with failure of late-stage study of drug for autoimmune disease

How 1 sources are covering this

• STATCenter·2h ago

  STAT+: Argenx sees unusual setback with failure of late-stage study of drug for autoimmune disease

  Argenx said its blockbuster drug Vyvgart didn’t outperform placebo in a Phase 3 trial of patients with Sjögren's disease, a chronic autoimmune disorder.

  Read at STAT →